Skip to main content
Minerva Neurosciences, Inc. logo

Minerva Neurosciences, Inc. — Investor Relations & Filings

Ticker · NERV ISIN · US6033802058 LEI · 54930017PANCHC5LYH79 US Manufacturing
Open in API
Filings indexed 589 across all filing types
Latest filing 2016-03-18 Director's Dealing
Country US United States of America
Listing US NERV

About Minerva Neurosciences, Inc.

https://www.minervaneurosciences.com/

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of product candidates for the treatment of central nervous system (CNS) diseases. The company's lead product candidate is roluperidone, which is being developed to treat the negative symptoms of schizophrenia. Minerva Neurosciences leverages its expertise in clinical development to design innovative trials with clinical endpoints aimed at demonstrating direct patient benefit.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2016-03-18 English
Regulatory Filings 2016
Regulatory Filings
2016-03-18 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated March 17, 2016, reporting the entry into a material definitive agreement involving a private placement of common stock. It details the sale of shares to an accredited investor and includes a Common Stock Purchase Agreement as an exhibit. The content focuses on a financing transaction and capital raising activity. There are no financial statements or earnings data presented, nor is it an announcement of a report publication or a certification. The primary subject is the company's capital raising through a private placement, which fits the Capital/Financing Update category.
2016-03-18 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock option plans or equity incentive plans. The text includes details about the securities to be registered, the equity incentive plan, and exhibits related to corporate governance documents and legal opinions. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories.
2016-03-14 English
10-K
Annual Report FY 2015
2016-03-14 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions that the filing includes a press release announcing top line results from a Phase Ib clinical trial. There are no financial statements or detailed financial data included in the text, only a reference to the press release as an exhibit. The document length is short (2559 characters), and it primarily serves as an announcement of the press release rather than a detailed report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and often includes current reports like Form 8-K filings that announce events or press releases.
2016-03-11 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.